EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents

Saubia Fathima, Margaret Mei-Kay Wong, Jesus Gonzalez-Lugo, Susan M Geyer iD, Ali Alsugair iD, Maria Sirenko, Kimberly J Langer, Terra L Lasho iD, Christy Finke, Jun Choi, Maher Abdul-Hay, Gary Ho iD und 37 weitere

American Journal of Hematology · 2026-09 · 101 (9) · 2166-2176

DOI: 10.1002/ajh.70401 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, online erschienen am 08.06.2026. Verfasst von Saubia Fathima und 48 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes, Azacitidine, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Mayo Clinic Center for Clinical and Translational Science, American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hypomethylating agents (HMA) and allogeneic hematopoietic stem cell transplantation (alloHSCT) have both demonstrated remissions in VEXAS; however, comparative data is lacking. We conducted a multicenter, retrospective analysis of 66 patients diagnosed with VEXAS syndrome treated with HMA ( n = 35) or alloHSCT ( n = 31). Baseline characteristics such as genetics, co‐morbidities, and performance status were balanced between the groups, except older age in the HMA group. Median follow‐up from therapy initiation was 18 months (95% CI: 11–26), and 14 (21%) deaths were reported (alloHSCT n = 3; HMA n = 11). Among all evaluable patients within the alloHSCT cohort, all patients achieved molecular remission, and a substantial proportion of patients discontinued glucocorticoids (58%). In contrast, HMA therapy was associated with lower but meaningful rates of molecular remission (22%) and glucocorticoid discontinuation (6%). In a real‐world setting, HMA therapy was associated with a high discontinuation rate related to toxicity or lack of response. On multivariable analysis adjusted for age and Charlson Comorbidity Index, alloHSCT was associated with improved overall survival (HR = 0.20, 95% CI: 0.05–0.81; p = 0.024). This association remained consistent across multiple ancillary sensitivity analyses, including restriction to transplant‐eligible patients, patients aged ≤ 75 years, 1:1 matching, and propensity score‐based weighted analyses. Although limited by retrospective design, these findings suggest that alloHSCT remains an attractive and potentially curative strategy in selected patients with VEXAS. Prospective validation of these findings is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationMyelodysplastic SyndromesAzacitidineAntimetabolites, AntineoplasticHumansFemaleRetrospective StudiesMaleMiddle AgedTransplantation, HomologousAdultTreatment OutcomeAgedRemission InductionSkin Diseases, Genetic

Stichwörter der Autor:innen

HMAUBA1VEXASallogeneic transplantationazacitidinemolecular remissionmyelodysplastic syndrome

Substanzen

AzacitidineAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
  • Center for Human Genetics and Genomics, New York University Grossman School of Medicine, New York, New York, USA.
  • Hematologic Malignancies and Cellular Therapeutics, Blood and Marrow Transplant, University of Kansas Cancer Center, Kansas City, Kansas, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
  • Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA.
  • Division of Rheumatology, Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.

ORCID-Profile: Susan M Geyer, Ali Alsugair, Terra L Lasho, Gary Ho, Urshila Durani, William J Hogan, Naseema Gangat, Antoine N Saliba, Ronald S Go, Kenneth J Warrington, Horatiu Olteanu, Hemant Murthy, Talha Badar, Yael Kusne, Saurabh Chhabra, Amelia Langston, James Foran, Matthew J Koster, David B Beck, Hassan B Alkhateeb, Abhishek A Mangaonkar

Förderung

  • Mayo Clinic Center for Clinical and Translational Science
  • American Cancer Society

Zitieren

APA

Fathima, S., Wong, M. M., Gonzalez-Lugo, J., Geyer, S. M., Alsugair, A., Sirenko, M., Langer, K. J., Lasho, T. L., Finke, C., Choi, J., Abdul-Hay, M., Ho, G., Litzow, M. R., Matin, A., Durani, U., Hefazi, M., Hogan, W. J., Shah, M. V., Al-Kali, A., …, & Mangaonkar, A. A. (2026). Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents. American Journal of Hematology, 101(9), 2166-2176. https://doi.org/10.1002/ajh.70401

Vancouver

Fathima S, Wong MM, Gonzalez-Lugo J, Geyer SM, Alsugair A, Sirenko M, et al. Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents. American Journal of Hematology. 2026;101(9):2166-2176. doi:10.1002/ajh.70401

BibTeX
@article{Fathima2026,
  author = {Fathima, Saubia and Wong, Margaret Mei-Kay and Gonzalez-Lugo, Jesus and Geyer, Susan M and Alsugair, Ali and Sirenko, Maria and Langer, Kimberly J and Lasho, Terra L and Finke, Christy and Choi, Jun and Abdul-Hay, Maher and Ho, Gary and Litzow, Mark R and Matin, Aasiya and Durani, Urshila and Hefazi, Mehrdad and Hogan, William J and Shah, Mithun V and Al-Kali, Aref and Begna, Kebede H and Gangat, Naseema and Saliba, Antoine N and Go, Ronald S and Kewan, Tariq and Bartoo, Gabriel and Kutzke, Jade and McCullough, Kristen and Warrington, Kenneth J and Sullivan, Megan and Reichard, Kaaren K and Olteanu, Horatiu and Murthy, Hemant and Badar, Talha and Kusne, Yael and Palmer, Jeanne and Chhabra, Saurabh and Punwani, Nathan and Riwes, Mary and McGuirk, Joseph P and Krakow, Elizabeth F and Langston, Amelia and Kourelis, Taxiarchis and Dingli, David and Foran, James and Koster, Matthew J and Patnaik, Mrinal M and Beck, David B and Alkhateeb, Hassan B and Mangaonkar, Abhishek A},
  title = {Therapeutic Outcomes in VEXAS Syndrome: A Multicenter Comparative Cohort of Allogeneic Hematopoietic Stem Cell Transplantation and Hypomethylating Agents},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {9},
  pages = {2166--2176},
  doi = {10.1002/ajh.70401}
}
Kostenlos starten →